Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Irritable Bowel Syndrome
NCT06201182Recruiting
- Sponsor
- Thammasat University
- Start
- Aug 2020
- Primary completion
- Aug 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Randomised, double-blind trial of allogeneic fecal microbiota in irritable bowel syndrome (IBS), sponsored by Thammasat University. Primary endpoint: Proportion of responders at 12 weeks. Started Aug 2020; status: recruiting.
02
Drugs
allogeneic fecal microbiota
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT06201182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201182.